Latest Urinary bladder Stories

Bladder augmentation enhances quality of life for patients suffering from neurological disease CHICAGO, June 20, 2011 /PRNewswire-USNewswire/ -- Andrew Baniecki dreamed of becoming a pilot for as long as he can remember. His passion for airplanes began when he was a small child opting to play with toy planes instead of cars, and grew when he took his first ride on an airplane during a family trip to Disney World. At 8-years old Baniecki scribbled down on a piece of paper his dream of...

EAST NORRITON, Pa., June 13, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided an update on the clinical trial of the Company's lead clinical product candidate, the Neo-Urinary Conduit(TM), for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy). Tengion is continuing to work with investigators to optimize the surgical approach as part of its ongoing clinical trial of the Neo-Urinary Conduit in patients with bladder cancer and...

A cell phone-sized, wireless near-infrared device is as reliable as the current "gold standard" invasive tests in determining bladder disease, according to a study by researchers at the University of British Columbia, Vancouver Coastal Health and the Child & Family Research Institute (CFRI).The new physiologic information gathered through near-infrared spectroscopy (NIRS) could also advance treatment that tackles the root causes of urinary incontinence, says the research team.Published in...

DEERFIELD, Ill., May 17, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc. (Tokyo: TSE: 4503, "the Company"), today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms - urinary incontinence (leakage of urine) and frequency of micturition...

Bladder cancer is the fourth-most-common cancer in men and one of the most expensive cancers to treat from diagnosis to death. After initial diagnosis and surgery, patients must return to the urologist at least yearly for a costly, time-consuming and uncomfortable bladder scan. Tumors recur in more than half of patients.Researchers at the University of Washington are proposing a more automated approach that could be cheaper, more comfortable and more convenient for both doctors and patients....

BETHESDA, Md., May 5, 2011 /PRNewswire/ -- The Bladder Cancer Advocacy Network (BCAN) today announced the launch of the Hope After Recurrence(TM) campaign -- an educational awareness program designed to provide support, information and hope to survivors with recurring non-muscle invasive bladder cancer and their loved ones. The campaign fills an important need with educational resources and community support for the recurring non-muscle invasive bladder cancer survivors in the United...

Much of the risk of developing incontinence before middle age is determined by our genes. Genetic factors can explain half of people's susceptibility to urinary incontinence, a study of twins at the University of Gothenburg and Karolinska Institutet (Sweden) reveals.Urinary incontinence is very common, especially among women, with around one in three affected at some point in life. Incontinence, overactive bladder and other lower urinary tract symptoms can be caused by factors such as old...

TOKYO, March 22, 2011 /PRNewswire-FirstCall/ -- Astellas Pharma Inc.(TSE:4503,"Astellas") ( http://www.astellas.com/en/corporate/) today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition[1,2]. These data were presented for the first time this week at...

EAST NORRITON, Pa., March 18, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Friday, March 25, 2011 at 8:30 a.m. EDT to provide a business update and discuss its fourth quarter 2010 financial results. To participate in the call, please dial 1-888-680-0879 (domestic) or 1-617-213-4856 (international) and reference access code 55045101. This conference call will also be webcast...

Fifth Most Frequently Diagnosed Cancer in U.S. Affects Approximately 70,000 Americans Each Year LOS ANGELES, March 3, 2011 /PRNewswire-USNewswire/ -- Bladder cancer is the fifth most commonly diagnosed cancer, and there are more than 600,000 survivors in the United States, yet most people know nothing about it. To help enhance the public's understanding of the risks and signs of bladder cancer and the importance of early detection and treatment options, the Bladder Cancer Advocacy Network...